SDI Health extends its longitudinal patient analytics to measure media impacts
A new Media Innovations Division within SDI Health (Plymouth Meeting, PA) aims to apply the same patient-level data (PLD) used for measuring market trends in prescribing and patient care to how those patients are affected by, among other things, direct-to-consumer (DTC) advertising. This would be of highest use to media buyers who might want to know, for example, the television-viewing habits of diabetes patients, but can also be useful for physician-based patient interactions, adherence programs and other types of patient interactions.
“Historically, media effectiveness has been measured by primary research—doing telemarketing campaigns to consumers and asking them to recall their impressions,” says David Nussbaum, VP of the new division. “Now, we can provide insights based on true patient and provider behavior.”
SDI Health is one of the pioneers in matching patient healthcare records (from hospitals or clinics) with prescription usage (from retail pharmacies) over time. All these types of data go into a “de-identification” process that matches datasets but removes patient identification, per HIPAA requirements. The new service, called HealthRatings, makes these results available to clients via a Web portal. “This addresses two of the most challenging issues for advertising pharmaceutical brands: How do I reach the right patient targets and what is my campaign ROI,” says Nussbaum.
An Exploration of Compounding Practices
May 22nd 2025In a Q&A with Pharma Commerce, Kurt Lunkwitz, ProRx Pharma’s COO, uncovers the stringent requirements that 503B outsourcing facilities must abide by under the Drug Quality and Security Act, while also shedding light on the FDA’s impact when it comes to improving the safety, quality, and trust in compounded drugs.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.